Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Symphogen Reports New Data on Anti-EGFR Monoclonal Antibody Mixture

Published: Monday, June 03, 2013
Last Updated: Monday, June 03, 2013
Bookmark and Share
ASCO presentation and poster on SYM004 in mCRC and SCCCHN.

Symphogen has announced at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO) the results of two proof-of-concept studies of SYM004, an anti-EGFR monoclonal antibody (mAb) mixture.

Symphogen entered the antibody mixture into the clinic in 2010, and subsequently partnered with Merck KGaA, Darmstadt, Germany, in September 2012.

In sessions this morning, Abstract #3551 provided data on SYM004’s clinical evaluation in patients with anti-EGFR mAb-resistant/refractory KRAS wild-type (wt) metastatic colorectal cancer (mCRC) and Abstract #6002 in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) refractory to anti-EGFR mAb.

Both studies provided data supportive of the anticipated mechanism of action of the antibody mixture.

Professor Jean-Pascal Machiels, Head of Department of Medical Oncology, Université Catholique de Louvain, Clinique Universitaires St-Luc, Brussels, Belgium, lead investigator in the Sym004-02 study who made the oral presentation, commented, "These datasets suggest an anti-tumor effect. The achievement of stable disease and tumor shrinkage in heavily pretreated patient populations is of interest for any potential treatment. The studies are in line with Symphogen’s published data on the mechanism of action. The fact that these patients had progressed on other EGFR mAbs suggest a potentially additive effect against the EGF receptor."

Squamous Cell Carcinoma of the Head and Neck (SCCHN) Phase 2 Open Label Study Results
Weekly doses of 12 mg/kg Sym004 showed clinical response of stable disease in half of the heavily pretreated SCCHN patients resistant/refractory to previous anti-EGFR mAb treatment.
• Tumor shrinkage was observed in 8/26 patients by central and blinded review of CT scans. SD was observed in 13/26 patients.
• Median PFS was 2.7 months (95% CI 1.4-4.7 months).
• The observed safety profile was similar to other anti-EGFR mAbs except for skin related toxicity
• EGFR down-modulation was observed in paired skin and tumor biopsies, supporting the proposed mechanism-of-action.

Metastatic Colorectal Cancer Phase 1 / 2 Results
Weekly doses of Sym004 showed clinical responses in mCRC patients failing previous anti-EGFR mAb treatment. Partial responses were seen at both the 12 mg/kg and 9 mg/kg doses:
• A central and blinded review of CT scans was performed in 27/29 patients treated with 12 mg/kg Sym004 and showed tumor shrinkage >10% in 7/27 (26%) pts. A partial response (PR) PR was observed in 3/27 (11%) and stable disease (SD) in 16/27 (59%).
• A central and blinded review of CT scans was performed in 12/13 patients treated with 9 mg/kg Sym004 and showed tumor shrinkage >10% in 4/12 (33%) pts. A PR was observed in 1/12 (8%) and SD in 8/12 (67%).
• PFS for 9 mg/kg and 12 mg/kg was 14 weeks (95% CI 5.3 - 22.1%) and 14.3 weeks (95% CI 6.0 - 18.6), respectively.
• The observed safety profile was similar to other anti-EGFR mAbs, except for skin related toxicity.
• EGFR down-modulation was observed in paired skin and tumor biopsies supporting the proposed mechanism-of-action.

Symphogen has an exclusive worldwide license agreement with Merck KGaA, of Darmstadt, Germany, for Sym004. Under the agreement, Merck gained exclusive worldwide rights to develop and commercialize Sym004.

Symphogen received from Merck in 2012 an upfront payment of € 20 million.

Symphogen is eligible to receive up to € 225 million for meeting clinical development and regulatory milestones, and € 250 million in potential sales performance milestones and royalties on net worldwide sales.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Symphogen’s Antibody Mixtures Highlighted in Three Peer-Reviewed Journals
Pioneering and novel approach to Anti-EGFR and Pan-HER antibodies validated in clinical and pre-clinical research papers.
Thursday, May 28, 2015
Symphogen to Report Preliminary Safety Data from a Phase 1 Study of Sym004
Data will be presented at the upcoming 2014 ASCO Annual Meeting in Chicago.
Friday, May 30, 2014
Symphogen Announces the Appointment of Annika Espander Jansson
Appointment of Annika as Non-Executive Director of the Board.
Monday, December 23, 2013
Symphogen Receives Milestone Payment in Merck KGaA Sym004 Collaboration
Payment enhances the financial position of Symphogen.
Wednesday, June 26, 2013
Symphogen Expands Previous Private Equity Round, Reaching a Total of € 141 Million
Novo A/S and PKA led the expansion with investments of €20 million each, while Danica Pension participated with its pre-financing ownership share of the additional financing.
Friday, May 03, 2013
Symphogen’s Success Attracts USD 25 Million Investment
The financing will be used to carry out clinical trials of Symphogen’s first product, anti-RhD.
Thursday, January 12, 2006
Scientific News
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
The Secret Behind the Power of Bacterial Sex
Migration between different communities of bacteria is the key to the type of gene transfer that can lead to the spread of traits such as antibiotic resistance, according to researchers at Oxford University.
Farming’s in Their DNA
Ancient genomes reveal natural selection in action.
GMO Food Animals Should be Judged by Product, Not Process
In a world with a burgeoning demand for meat, milk and eggs, regulatory policies around the use of biotechnologies in agriculture need to be based on the safety and attributes of those foods rather than on the methods used to produce them, says a UC Davis animal scientist.
Enzyme Critical to Maintaining Telomere Length Discovered
New method expected to speed understanding of short telomere diseases and cancer.
Gene Drive Reversibility Introduces New Layer of Biosafety
Ability to introduce or reverse the spread of genetic traits through populations could one day improve pest management and disease control.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos